Omnicell’s (OMCL) Overweight Rating Reaffirmed at Piper Sandler

Omnicell (NASDAQ:OMCL)‘s stock had its “overweight” rating reiterated by equities research analysts at Piper Sandler in a research note issued to investors on Monday,Benzinga reports. They presently have a $45.00 price objective on the stock, down from their prior price objective of $55.00. Piper Sandler’s price objective would suggest a potential upside of 21.70% from the company’s current price.

Several other equities research analysts have also recently commented on OMCL. Wall Street Zen raised Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Zacks Research cut shares of Omnicell from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Wells Fargo & Company dropped their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday. Craig Hallum restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research note on Wednesday, April 29th. Finally, KeyCorp dropped their price target on Omnicell from $70.00 to $65.00 and set an “overweight” rating on the stock in a research note on Friday. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.86.

Omnicell Trading Up 4.5%

Shares of OMCL stock traded up $1.60 on Monday, hitting $36.98. The company had a trading volume of 238,920 shares, compared to its average volume of 659,464. Omnicell has a twelve month low of $29.06 and a twelve month high of $55.00. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. The firm has a market cap of $1.68 billion, a P/E ratio of 43.91, a P/E/G ratio of 0.92 and a beta of 0.98. The stock’s 50-day moving average is $41.97 and its two-hundred day moving average is $41.02.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The company’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. On average, equities research analysts anticipate that Omnicell will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Omnicell

In related news, EVP Corey J. Manley sold 5,025 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the transaction, the executive vice president owned 112,783 shares in the company, valued at approximately $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $43.22, for a total transaction of $133,549.80. Following the completion of the transaction, the executive vice president owned 154,785 shares in the company, valued at approximately $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 2.92% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Omnicell

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Versant Capital Management Inc grew its stake in Omnicell by 38.7% in the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after buying an additional 294 shares in the last quarter. Cerity Partners LLC grew its position in shares of Omnicell by 4.9% in the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock valued at $345,000 after purchasing an additional 354 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Omnicell by 1.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after purchasing an additional 424 shares during the period. Legal & General Group Plc raised its stake in shares of Omnicell by 0.3% during the 3rd quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock valued at $4,823,000 after purchasing an additional 448 shares during the period. Finally, First Horizon Corp boosted its stake in Omnicell by 54.6% in the 4th quarter. First Horizon Corp now owns 1,597 shares of the company’s stock worth $72,000 after purchasing an additional 564 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.